{'fraction_non_alphanumeric': 0.01780821917808219, 'fraction_numerical': 0.010958904109589041, 'mean_word_length': 5.6454545454545455, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Detection of p21ras mutations in colorectal adenomas and carcinomas by enzyme‐linked immunosorbent assay

Background. Point mutations of the ras protooncogene, primarily within codons 12 and 13, are commonly identified in colorectal carcinomas and large adenomas. Despite data suggesting that ras genotyping may have clinical significance with respect to colorectal cancer screening and prognosis, more widespread use has been limited because of the lack of a suitable assay system. The principal objective of this study was to assess the feasibility and validity of a qualitative enzyme‐linked immunosorbent assay (ELISA) fair detecting the four most common ras mutations in human colorectal tumors at the protein (p21ras) level.